iosBio

iosBio believes that thermally stable, self-administered vaccines in capsule form are the future. Due to its OraProTM platform, these are inexpensive to produce, developed in weeks and, following regulatory approval, can be distributed by mail. iosBio is using this approach to tackle the global COVID-19 pandemic, developing a capsule-based vaccine that could be easily distributed to millions across the globe. This comes after successfully working on an oral vaccine for the Zika virus. iosBios OraProTM technology means these thermally stable viral vector-based vaccines can be delivered in capsule form to the GI tract. Viral vectors result in vaccines being developed...

Vaccine stability,oral gene therapy platform,biologic stability,influenza vaccine,zika vaccine,cold chain enhancement,oral viral vectored proteins,and thermostability

Iosbio operates in the Biotechnology research industry.

Iosbio's revenue is 11m - 100m

Iosbio has 11 - 50 employees.